
Johnson & Johnson
JNJ · NYSE · Pharmaceuticals
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $690 bn
- Div. yield
- 3,1%
- Year to date
- +38,1%
Ratio score
based on 8 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
2 ✓ · 3 — · 3 ✕ · 2 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 42,9 | 22,9 | 41,8 |
| Forward P/E | 23,7 | — | 12,4 |
| PEG | 4,6 | — | 3,3 |
| P/S | 6,9 | 5,2 | 3,4 |
| EV/EBITDA | 28,1 | 18,3 | 24,0 |
| P/FCF | 33,5 | — | 14,0 |
| P/B | 8,5 | 5,7 | 8,1 |
Industry median — across 6 profitable companies in “Pharmaceuticals” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 30 analysts
- Buy
- 21
- Hold
- 9
- Sell
- 0
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 2,56 | 2,59 | Up +1,0% |
| Q2 2026 | 2,87 | 2,90 | Up +0,9% |
| Q1 2026 | 2,69 | 2,70 | Up +0,3% |
| Q4 2025 | 2,46 | 2,46 | Down −0,1% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25,4 bn | 25,3 bn | 24,1 bn | 24,6 bn | 24,0 bn | 23,7 bn | 21,9 bn | 22,5 bn | 22,5 bn | 22,4 bn | 21,4 bn | 21,4 bn |
| EPS | 0,09 | 2,27 | 2,14 | 2,09 | 2,12 | 2,29 | 4,54 | 1,41 | 1,11 | 1,93 | 1,34 | 1,67 |
| Margin | 0,8% | 21,9% | 21,8% | 20,8% | 21,5% | 23,3% | 50,2% | 15,2% | 12,0% | 20,9% | 15,2% | 18,9% |
| FCF | 6,36 bn | 7,30 bn | 1,47 bn | 5,47 bn | 8,01 bn | 2,84 bn | 3,38 bn | 5,37 bn | 6,96 bn | 4,66 bn | 2,85 bn | 6,27 bn |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: purchases $257 688 (1 person), sales $154 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| forminard elizabeth12 Nov 2026 · sale | $3,72 m | 13 072 | $284,39 |
| schmid timothy2 Sep 2026 · sale | $6,19 m | 22 527 | $274,74 |
| schmid timothy2 Sep 2026 · sale | $3,04 m | 11 070 | $274,74 |
| taubert jennifer l17 Aug 2026 · sale | $3,95 m | 15 000 | $263,36 |
| duato joaquin13 Aug 2026 · sale | $26,7 m | 102 315 | $261,00 |
| duato joaquin13 Aug 2026 · sale | $5,50 m | 20 976 | $262,00 |
| forminard elizabeth6 Aug 2026 · sale | $1,68 m | 6 574 | $255,93 |
| forminard elizabeth6 Aug 2026 · sale | $2,41 m | 9 344 | $257,76 |
| duato joaquin5 Aug 2026 · sale | $1,69 m | 6 523 | $258,74 |
| duato joaquin5 Aug 2026 · sale | $10,8 m | 41 957 | $258,06 |
| broadhurst vanessa20 Jul 2026 · sale | $5,79 m | 23 054 | $251,27 |
| wengel kathryn e11 Jun 2026 · sale | $2,41 m | 10 000 | $241,15 |
| decker robert j27 Feb 2026 · sale | $1,01 m | 4 075 | $247,87 |
| schmid timothy20 Feb 2026 · sale | $324 763 | 1 322 | $245,66 |
| schmid timothy18 Feb 2026 · sale | $2,20 m | 8 998 | $244,53 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Pharmaceuticals
- Exchange
- NYSE
- Country
- US
- IPO date
- 25 Sep 1944
- Website
- www.jnj.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
MRKMerck & Co. | $144,46 | 38★★★★★★★would not consider | 148,5 | +4,9% | 3,6% |
LLYLilly (Eli) | $1 431,67 | 75★★★★★★★★★would consider | 49,2 | +45,5% | 31,9% |
PFEPfizer | $28,86 | 44★★★★★★★would watch | 40,8 | +1,3% | 6,3% |
BMYBristol Myers Squibb | $62,93 | 81★★★★★★★★★would consider | 14,0 | +4,2% | 18,5% |
ZTSZoetis | $84,39 | 75★★★★★★★★★would consider | 12,4 | +1,2% | 26,1% |
Ratio — a score by our methodology, not an investment recommendation.




